Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

a technology of lymphotoxin beta and blockade, which is applied in the field of treating viral-induced systemic shock and respiratory distress, can solve the problems of little known about the pathogenesis of these viruses and how to effectively treat the thousands of patients

Inactive Publication Date: 2009-04-02
EMORY UNIVERSITY +1
View PDF22 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]The foregoing and other objects, features, aspects and advantages of the present invention, as well as the invention itself, will be more fully understood from the following description of preferred embodiments.

Problems solved by technology

Little is currently known about the pathogenesis of these viruses nor how to effectively treat the thousands of patients infected globally each year suffering from viral-induced systemic shock and respiratory distress.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
  • Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
  • Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Examples

Experimental program
Comparison scheme
Effect test

example

[0092]Tumor necrosis factor (TNF α) plays a key role in facilitating acute shock responses to viral infections and other immunogens (K. C. F. Sheehan, N. H. Ruddle, and R. D. Schreiber., J. Immunol., 142, 3884 (1989); G. W. H. Wong and D. V. Goeddel Nature 323, 819 (1986); B. Beutler, I. W. Milsark, A. Cerami, Science 229, 869 (1985); F. Mackay, P. R. Bourdon, D. A. Griffiths, et al. J. Immunol. 159, 3299 (1997); P. D. Crowe, T. L. VanArsdale, B. N. Walter, et al. Science 264, 707 (1994)). During episodes of Dengue Fever involving shock, levels of TNFα in sera from patients are elevated as are levels of soluble TNFR-75 (D. Hober, et al., J. Trop. Med. Hyg., 48, 324 (1993); D. B. Bethell, K. Flobbe, C. X. T. Phuong, et al., J. Infect. Dis., 177, 778 (1998)). We measured TNFα levels in the sera of mice infected with a variant of lymphocytic choriomeningitis virus, LCMV, Clone 13 (LCMV-13) (HH, II). TNFα levels in the sera of mice infected with LCMV-13 were found to be just above the l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
temperatureaaaaaaaaaa
solubleaaaaaaaaaa
Login to view more

Abstract

This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

Description

RELATED APPLICATIONS[0001]This is a continuation of U.S. patent application Ser. No. 10 / 829,720, filed on Apr. 21, 2004, which is a continuation of U.S. patent application Ser. No. 09 / 829,031, filed on Apr. 9, 2001, which is a continuation of PCT / US99 / 23477, filed on Oct. 8, 1999 as a continuation-in-part of prior U.S. Provisional No. 60 / 103,662 filed Oct. 9, 1998. The entire contents of each of the aforesaid patent applications are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention relates generally to methods of inducing an antiviral response in an individual. In particular, this invention provides methods for treating viral-induced systemic shock and respiratory distress in an individual. The methods involves administration of certain “lymphotoxin-beta blocking agents”.BACKGROUND OF THE INVENTION[0003]Several viruses including Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue all cause acute diseases with many of the following symptoms...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/19A61P31/12A61K38/00A61K38/17A61K45/00A61K38/22C07K16/24C07K16/28
CPCA61K38/191A61K2039/505C07K16/241A61K38/1793C07K16/2866C07K2319/30C07K16/242A61P11/00A61P11/16A61P31/12A61P37/00Y02A50/30A61K39/395
Inventor BROWNING, JEFFREYPUGLIELLI, MARYANNAHMED, RAFI
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap